Risperidone long-acting injectable for maintenance therapy in bipolar disorder: An open-label pilot study

International Journal of Psychiatry in Clinical Practice

Volumn 12, Issue 1, 2008, Pages 74-77

  Bräunig, Peter ^a,d   Sacchetti, Emilio ^b   Medori, Rossella ^c  

^a VIVANTES HOSPITAL   (Germany)

^b Spedali Civili di Brescia   (Italy)

^c Janssen Cilag EMEA Belgium   (Belgium)

^d NONE   (Germany)

Author keywords

Bipolar I; Efficacy; Long acting risperidone; Maintenance; Symptom control

Indexed keywords

ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ANXIETY; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DYSTONIA; FEMALE; HUMAN; INSOMNIA; MAINTENANCE THERAPY; MALE; MANIA; MENTAL DISEASE; MOOD DISORDER; MULTICENTER STUDY; OPEN STUDY; PARKINSONISM; PATIENT COMPLIANCE; PATIENT SATISFACTION; PILOT STUDY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RATING SCALE; SIDE EFFECT; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN;

EID: 45849105867     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500701538161     Document Type: Article

References (28)

1. Sachs GS. Unmet clinical needs in bipolar disorder. J Clin Psychopharmacol 2003;23:S2-8.
2. Prien RF, Potter WZ. NIMH workshop report on treatment of bipolar disorder. Psychopharmacol Bull 1990;26:409-27.
3. Ertugrul A, Meltzer HY. Antipsychotic drugs in bipolar disorder. Int J Neuropsychopharmacol 2003;6:277-84.
4. Mensink GJR, Slooff CJ. Novel antipsychotics in bipolar and schizoaffective mania. Acta Psychiatr Scand 2004;109:405-19.
5. McIntyre R, Katzman M. The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disord 2003;5:20-35.
6. McIntyre RS, Mancini DA, Srinivasan J, McCann S, Konarski JZ, Kennedy SH. The antidepressant effects of risperidone and olanzapine in bipolar disorder. Can J Clin Pharmacol 2004;11:e218-26.
7. Bowden CL. Making optimal use of combination pharmacotherapy in bipolar disorder. J Clin Psychiatry 2004;65:21-4.
8. Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998;21:176-80.
9. Vieta E, Brugue E, Goikolea JM, et al. Acute and continuation risperidone monotherapy in mania. Hum Psychopharmacol Clin Exp 2004;19:41-5.
10. Hirschfeld RMA, Keck PE, Kramer M, Canuso C, Eerdekens M, Grossman F. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004;161:1057-65.
11. Yatham LN, Binder C, Kusumakar V, Riccardelli R. Risperidone plus lithium versus risperidone plus valproate in acute and continuation treatment of mania. Int Clin Psychopharmacol 2004;19:103-9.
12. Yatham LN, Binder C, Riccardelli R, Leblanc J, Connolly M, Kusumakar V. Risperidone in acute and continuation treatment of mania. Int Clin Psychopharmacol 2003;18:227-35.
13. Bowden CL, Myers JE, Grossman F, Xie Y. Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder. J Clin Psychiatry 2004;65:707-14.
14. Conte G, Parrinello G. Risperidone versus haloperidol in the long-term treatment of bipolar patients with psychotic symptoms: a naturalistic study. European Conference of Neuropsychopharmacology, 2003.
15. Vieta E, Goikolea JM, Corbella B, et al. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J Clin Psychiatry 2001;62:818-25.
16. Vieta E, Gasto C, Colom F, et al. Role of risperidone in bipolar II: an open 6-month study. J Affect Disord 2001;67:213-9.
17. Moller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005;20:121-30.
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Washington, DC: American Psychiatric Association; 1994.
19. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub. No. (ADM) . Rockville: Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. pp 218-20.
20. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
21. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-46.
22. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. Extrapyramidal symptom rating scale. Can J Neurol Sci 1980;7:233.
23. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 1978;133:429-35.
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
25. Chue P. Risperidone long-acting injection. Expert Rev Neurotherapeutics 2003;3:435-46.
26. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second generation antipsychotic. J Clin Psychiatry 2003;64:1250-7.
27. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-32.
28. Sachs G, Bowden C, Calabrese JR, et al. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disord 2006;8:175-81.